DDIapp—A Web-Based Application for Static Drug–Drug Interaction Assessment

IF 2.8 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Hirotaka Watase, Sylvie Klieber, Yorgos M. Psarellis, Nikhil Pillai, Panteleimon D. Mavroudis, Saroj Dhakal
{"title":"DDIapp—A Web-Based Application for Static Drug–Drug Interaction Assessment","authors":"Hirotaka Watase,&nbsp;Sylvie Klieber,&nbsp;Yorgos M. Psarellis,&nbsp;Nikhil Pillai,&nbsp;Panteleimon D. Mavroudis,&nbsp;Saroj Dhakal","doi":"10.1002/psp4.70300","DOIUrl":null,"url":null,"abstract":"<p>In this work we describe the development of a web-based application for static drug–drug interaction (DDI) risk assessment in accordance with the International Council for Harmonization (ICH) M12 guidance. The app was built using the Shiny for Python framework and it employs a modular mathematical modeling structure that incorporates models for the assessment of enzyme inhibition, enzyme induction, and transporter inhibition at intestinal, hepatic, and renal levels. In addition, a “net effect” model estimates the combined impact of inhibition and induction on victim drug exposure, expressed as the area under the curve ratio (<i>AUCR</i>). Matrix-specific approaches for estimating unbound fractions in microsomes and hepatocytes (<i>f</i><sub>u,mic</sub> and <i>f</i><sub>u,hep</sub>), as indicated in regulatory alignment, are implemented. The application provides a dynamic interface that supports flexible parameter input, real-time evaluation across multiple DDI scenarios, and automated risk categorization using predefined thresholds based on the ICH M12 guidelines, with visual cues to aid risk interpretation. Additional features include integrated equation display for transparency and interpretation, export capabilities to PDF and Excel formats and a glossary with links to guidance documents and resources from major regulatory authorities (FDA, EMA, PMDA and NMPA). This DDIapp is validated against Certara's drug–drug interaction calculator under ICH M12 evaluation conditions. DDIapp offers a user-friendly platform for assessing the risk of pharmacokinetic drug interactions as a perpetrator involving metabolic enzymes and transporters, supporting both scientific research and regulatory decision-making.</p>","PeriodicalId":10774,"journal":{"name":"CPT: Pharmacometrics & Systems Pharmacology","volume":"15 8","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2026-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13401703/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CPT: Pharmacometrics & Systems Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/psp4.70300","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

In this work we describe the development of a web-based application for static drug–drug interaction (DDI) risk assessment in accordance with the International Council for Harmonization (ICH) M12 guidance. The app was built using the Shiny for Python framework and it employs a modular mathematical modeling structure that incorporates models for the assessment of enzyme inhibition, enzyme induction, and transporter inhibition at intestinal, hepatic, and renal levels. In addition, a “net effect” model estimates the combined impact of inhibition and induction on victim drug exposure, expressed as the area under the curve ratio (AUCR). Matrix-specific approaches for estimating unbound fractions in microsomes and hepatocytes (fu,mic and fu,hep), as indicated in regulatory alignment, are implemented. The application provides a dynamic interface that supports flexible parameter input, real-time evaluation across multiple DDI scenarios, and automated risk categorization using predefined thresholds based on the ICH M12 guidelines, with visual cues to aid risk interpretation. Additional features include integrated equation display for transparency and interpretation, export capabilities to PDF and Excel formats and a glossary with links to guidance documents and resources from major regulatory authorities (FDA, EMA, PMDA and NMPA). This DDIapp is validated against Certara's drug–drug interaction calculator under ICH M12 evaluation conditions. DDIapp offers a user-friendly platform for assessing the risk of pharmacokinetic drug interactions as a perpetrator involving metabolic enzymes and transporters, supporting both scientific research and regulatory decision-making.

Abstract Image

ddiapp -基于web的静态药物-药物相互作用评估应用。
在这项工作中,我们描述了基于web的静态药物-药物相互作用(DDI)风险评估应用程序的开发,按照国际协调理事会(ICH) M12指南。该应用程序是使用Shiny for Python框架构建的,它采用了模块化的数学建模结构,结合了肠道、肝脏和肾脏水平的酶抑制、酶诱导和转运蛋白抑制评估模型。此外,一个“净效应”模型估计了抑制和诱导对受害者药物暴露的综合影响,用曲线下面积比(AUCR)表示。矩阵特异性方法用于估计微粒体和肝细胞(fu,mic和fu,hep)中未结合的部分,如调节校准所示,被实施。该应用程序提供了一个动态界面,支持灵活的参数输入,跨多个DDI场景的实时评估,并使用基于ICH M12指南的预定义阈值进行自动风险分类,并提供可视化提示来帮助解释风险。其他功能包括集成的公式显示,透明度和解释,导出到PDF和Excel格式的功能,以及与主要监管机构(FDA, EMA, PMDA和NMPA)的指导文件和资源链接的术语表。该DDIapp在ICH M12评价条件下根据Certara的药物-药物相互作用计算器进行验证。DDIapp提供了一个用户友好的平台,用于评估涉及代谢酶和转运蛋白的药代动力学药物相互作用的风险,支持科学研究和监管决策。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.00
自引率
11.40%
发文量
146
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书